Health System

Dupilumab Clinically Effective Long Term for Moderate to Severe Pediatric Atopic Dermatitis

May 17th 2022, 7:45pm


Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.

Contributor: The Convergence of Value-Based Care and Lab Testing Growth

May 17th 2022, 5:15pm


Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.

Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis

May 16th 2022, 7:45pm


Significantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.

Dupilumab Improves Lung Function, Asthma Attacks in Children With Atopic Comorbidities

May 16th 2022, 4:30pm


Dupilumab improved lung function and reduced severe asthma exacerbation rates in children with moderate to severe asthma with or without atopic comorbidities.

What We're Reading: FDA Addressing Baby Formula Imports; Nivolumab, Ipilimumab in Urothelial Carcinoma; Antibiotics Linked With IBD

May 16th 2022, 2:30pm


FDA to make an announcement regarding importation of baby formula; first-line use of nivolumab and ipilimumab vs standard of care chemotherapy fails to meet primary end point of overall survival in phase 3 CheckMate 901 trial; study finds link between antibiotic prescriptions and inflammatory bowel disease diagnosis in older adults.

Greater Psoriatic Arthritis Activity, Impact Observed in Low-Income Countries

May 14th 2022, 6:40pm


Patients with psoriatic disease who live in low-income countries exhibited the highest disease activity and impact despite similar usage of biologic drugs to that of higher-income areas.

AJMC® in the Press, May 13, 2022

May 13th 2022, 2:28pm


Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Dr Robert Sidbury Discusses Strategies to Promote Earlier Uptake of Novel Atopic Dermatitis Therapies

May 13th 2022, 1:20pm


Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.

Study Finds Rural Residence May Adversely Influence Lung Cancer Screening Among Veterans

May 12th 2022, 9:45pm


Veterans residing in rural areas were less likely to complete annual repeat lung cancer screenings compared with those living in a nonrural location, with reduced uptake of initial lung cancer screening also found among eligible veterans in rural vs nonrural locations.

Oral Hygiene Reduces Chance of Ventilator-Associated Pneumonia in ICU Patients, Study Shows

May 11th 2022, 9:07pm


Oral care decreased both the number of intensive care unit (ICU) patients and the length of stay, as well as the amount of time of mechanical ventilation.